Evidence map›Paper›PMID 41726854›Full record

ArticleNIHR open research2025

Empirical oral AntibioticS for possible UTI in well appearing Young febrile infants (EASY).

Thomas Waterfield, Ronan McMullan, Mark D Lyttle, Stuart Hartshorn, Kerry Woolfall, Sanjay Patel, Wesley Hayes, Andrew Marshall, Kathryn Ferris, Ashley Agus and 5 more

Abstract read
In one paragraph

Article in NIHR open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thomas WaterfieldQueen's University Belfast, Belfast, Northern Ireland, UK.ORCID https://orcid.org/0000-0001-9452-7716
Ronan McMullanHCS Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
Mark D LyttlePerth Children's Hospital Foundation, Perth, Western Australia, Australia.ORCID https://orcid.org/0000-0002-8634-7210
Stuart HartshornChildren's Emergency Department, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Kerry WoolfallUniversity of Liverpool Department of Public Health Policy and Systems, Liverpool, England, UK.
Sanjay PatelUniversity Hospital Southampton NHS Foundation Trust, Southampton, England, UK.
Wesley HayesGreat Ormond Street Hospital Children's Charity, London, England, UK.
Andrew MarshallOxford University Hospitals NHS Foundation Trust, Oxford, England, UK.ORCID https://orcid.org/0000-0003-0529-0425
Kathryn FerrisQueen's University Belfast, Belfast, Northern Ireland, UK.ORCID https://orcid.org/0000-0001-5220-7466
Ashley AgusNorthern Ireland Clinical Trials Unit, Belfast, UK.
Christina CampbellNorthern Ireland Clinical Trials Unit, Belfast, UK.
Rachael RiceNorthern Ireland Clinical Trials Unit, Belfast, UK.
Andrew JacksonNorthern Ireland Clinical Trials Unit, Belfast, UK.
Lynn MurphyNorthern Ireland Clinical Trials Unit, Belfast, UK.ORCID https://orcid.org/0000-0001-9263-6337
Mike ClarkeNorthern Ireland Clinical Trials Unit, Belfast, UK.ORCID https://orcid.org/0000-0002-2926-7257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Urinary tract infections (UTIs) are the most common serious bacterial infections in febrile infants. Current UK guidelines recommend parenteral antibiotics for infants under three months with suspected UTI, despite evidence supporting oral therapy in low-risk infants. Objectives: To assess whether oral antibiotics are non-inferior to parenteral antibiotics for treating suspected UTIs based on treatment failure, need for additional therapy, and secondary outcomes. Design: Multicentre, randomised controlled, open-label, non-inferiority trial with embedded internal pilot. Setting: Twenty one paediatric emergency departments and assessment units across the UK. Participants: Infants aged 29-90 days with suspected UTI, abnormal urinalysis, and low risk of invasive bacterial infection. Exclusion criteria included prematurity, prior hospitalisation, structural renal abnormalities, and clinical signs of sepsis or meningitis. Interventions: Participants were randomised 1:1 to receive either oral antibiotics or standard care with intravenous (IV) antibiotics for 36-48 hours pending urine culture results. Main outcome measures: The primary outcome was the requirement for additional parenteral antibiotics within seven days of randomisation. A range of secondary outcomes were also planned, including treatment failure, time to recovery, adverse events, antibiotic adherence, quality of life, family impact, and healthcare resource use.Feasibility outcomes collected during the internal pilot included recruitment rate, site activation, protocol adherence, and retention. Clinical outcomes were collected but not powered for formal comparison. Results: 27 participants were recruited between 20 May 2024 and 13 March 2025 (which included the 6 month internal pilot), representing 27% of the pilot target. Protocol adherence was high, and no cases of meningitis occurred. Two cases of bacteraemia (one per randomised group) had uncomplicated clinical courses. Oral therapy was associated with shorter hospital stays and reduced parental time off work. Conclusions: While trial procedures were successfully implemented, recruitment challenges suggest that a larger randomised trial of this treatment comparison is not feasible in this setting. Trial management: Northern Ireland Clinical Trials Unit (NICTU). Trial registration: ISRCTN Clinical Trials Registry, ISRCTN10907780, Trial Dates 20 May 2024 to 13 March 2025.

Indexed as

antibioticsinfantPaediatricsurinary tract infection

Identifiers

PMID41726854
PMCPMC12924012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.